ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

In this conference update video, Prof. Valentina Guarneri, Prof. Matteo Lambertini, and Prof. Federico Rojo summarise the key points presented at the highly anticipated EBCC-14 Industry Satellite Symposium and review the current and future treatment landscape for ER+/HER2- advanced breast cancer, with a focus on the metastatic luminal subtype.

Topics of discussion include:

• Overview of the ESMO metastatic breast cancer living guidelines
• Impact of endocrine resistance and sensitivity
• The benefit of biomarker-selected endocrine-based therapies in ER+/HER2- advanced breast cancer
• ESR1 mutation: clinical significance and testing strategies

Clinical Takeaways

• Biomarker-selected endocrine therapies show greater PFS benefits in specific patient subgroups
• Elacestrant, the first oral SERD to obtain FDA & EMA approval, demonstrates optimal efficacy in ESR1-mutated ER+/HER2- mBC following CDK4/6i treatment
• Capivasertib, FDA-approved based on the CAPItello-291 study for AKT-pathway altered population, awaits EMA approval as of March 2024
• ESR1 mutation, holding both prognostic and predictive value, warrants testing upon ET recurrence or progression, using tissue or liquid biopsy